Biotage Past Earnings Performance
Past criteria checks 2/6
Biotage has been growing earnings at an average annual rate of 7.1%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 13.4% per year. Biotage's return on equity is 6.1%, and it has net margins of 11.9%.
Key information
7.1%
Earnings growth rate
5.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 13.4% |
| Return on equity | 6.1% |
| Net Margin | 11.9% |
| Next Earnings Update | 16 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biotage makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,981 | 236 | 695 | 174 |
| 31 Dec 23 | 1,862 | 246 | 636 | 159 |
| 30 Sep 23 | 1,603 | 189 | 601 | 140 |
| 30 Jun 23 | 1,555 | 216 | 558 | 125 |
| 31 Mar 23 | 1,541 | 240 | 546 | 112 |
| 31 Dec 22 | 1,566 | 268 | 529 | 109 |
| 30 Sep 22 | 1,524 | 240 | 494 | 107 |
| 30 Jun 22 | 1,428 | 228 | 467 | 98 |
| 31 Mar 22 | 1,337 | 216 | 432 | 96 |
| 31 Dec 21 | 1,232 | 205 | 396 | 91 |
| 30 Sep 21 | 1,188 | 203 | 372 | 80 |
| 30 Jun 21 | 1,145 | 187 | 353 | 76 |
| 31 Mar 21 | 1,096 | 174 | 355 | 73 |
| 31 Dec 20 | 1,092 | 175 | 375 | 72 |
| 30 Sep 20 | 1,083 | 149 | 394 | 76 |
| 30 Jun 20 | 1,103 | 179 | 417 | 79 |
| 31 Mar 20 | 1,131 | 201 | 415 | 79 |
| 31 Dec 19 | 1,101 | 187 | 399 | 79 |
| 30 Sep 19 | 1,047 | 196 | 375 | 77 |
| 30 Jun 19 | 997 | 173 | 352 | 72 |
| 31 Mar 19 | 951 | 170 | 339 | 70 |
| 31 Dec 18 | 911 | 168 | 324 | 66 |
| 30 Sep 18 | 865 | 175 | 309 | 59 |
| 30 Jun 18 | 811 | 162 | 292 | 60 |
| 31 Mar 18 | 771 | 148 | 275 | 56 |
| 31 Dec 17 | 748 | 139 | 262 | 56 |
| 30 Sep 17 | 738 | 122 | 262 | 53 |
| 30 Jun 17 | 728 | 118 | 259 | 52 |
| 31 Mar 17 | 694 | 105 | 253 | 52 |
| 31 Dec 16 | 668 | 93 | 245 | 49 |
| 30 Sep 16 | 657 | 96 | 234 | 52 |
| 30 Jun 16 | 640 | 87 | 230 | 51 |
| 31 Mar 16 | 625 | 78 | 224 | 49 |
| 31 Dec 15 | 611 | 73 | 222 | 50 |
| 30 Sep 15 | 580 | 83 | 214 | 47 |
| 30 Jun 15 | 549 | 75 | 204 | 44 |
| 31 Mar 15 | 521 | 75 | 196 | 43 |
| 31 Dec 14 | 490 | 65 | 187 | 38 |
| 30 Sep 14 | 474 | 53 | 182 | 35 |
| 30 Jun 14 | 459 | 49 | 178 | 34 |
| 31 Mar 14 | 455 | 46 | 178 | 34 |
| 31 Dec 13 | 445 | 41 | 177 | 33 |
| 30 Sep 13 | 437 | 37 | 178 | 33 |
| 30 Jun 13 | 441 | 33 | 181 | 35 |
Quality Earnings: PQX1 has high quality earnings.
Growing Profit Margin: PQX1's current net profit margins (11.9%) are lower than last year (15.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PQX1's earnings have grown by 7.1% per year over the past 5 years.
Accelerating Growth: PQX1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PQX1 had negative earnings growth (-1.7%) over the past year, making it difficult to compare to the Life Sciences industry average (6.5%).
Return on Equity
High ROE: PQX1's Return on Equity (6.1%) is considered low.